
CLPT
Clearpoint Neuro Inc
Health Care
Clearpoint Neuro Inc (CLPT) Stock News
The latest CLPT headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.